Indaptus Therapeutics
INDP
5 hedge funds and large institutions have $8.47M invested in Indaptus Therapeutics in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
17% less funds holding
Funds holding: 6 → 5 (-1)
29% less capital invested
Capital invested by funds: $11.9M → $8.47M (-$3.42M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
+$724K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$93.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
-$2.91M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.03M |
| 3 |
Renaissance Technologies
New York
|
-$81.7K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$58.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $4.62M | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $2.93M | +$93.4K | +8 | +4% |
|
|
NC
3
Nexthera Capital
New York
| $791K | +$724K | +62 | New |
|
|
4
Renaissance Technologies
New York
| $64K | -$81.7K | -7 | -58% |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $63K | -$58.4K | -5 | -50% |
|
6
UBS Group
Zurich,
Switzerland
| $5K | – | – | – |
|
|
MIFH
7
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
| – | -$2.91M | -221 | Closed |
|
|
OM
8
Opaleye Management
Boston,
Massachusetts
| – | -$1.03M | -78 | Closed |
|
INDP Hedge Fund Activity: Q4 2016 in Review
5 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2016, worth a combined $8.47M — down 29% from $11.9M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of INDP and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Nexthera Capital, opening a new position worth an estimated $724K. The largest seller was Migdal Insurance & Financial Holdings, exiting entirely with an estimated $2.91M sold.
- 5 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2016, down from 6 in Q3 2016.
- Funds reported $8.47M of Indaptus Therapeutics stock for Q4 2016, down 29% quarter-over-quarter.
- 1 fund opened new Indaptus Therapeutics positions in Q4 2016 and 2 closed out, a net change of -1 holder.
- The largest Indaptus Therapeutics buyer in Q4 2016 was Nexthera Capital, an estimated $724K added.
- The largest Indaptus Therapeutics seller in Q4 2016 was Migdal Insurance & Financial Holdings, an estimated $2.91M sold.
Based on aggregated 13F filings for Q4 2016.